Cell-based Transplantation

I did the mesenchymal stem cell clinical trial. It's been unblinded, I got the real dose not placebo.

My case hasn't shown a significant progression but that's true for the times before, during, and after the trial. Some things seem to have gotten better but also I'm just kinda used to them being there.

Those were administered by regular old IV, so they could in theory help things anywhere in the body. I was holding out for regrowing hair, which isn't just "nice"- it would be objective evidence that it does something. No improvement in hair to report, though.

Didn't get any sense of smell back either- it would be really exciting to see that, again, not just because it would be nice to smell coffee brewing again but, again, that would be objective proof of it helping since that almost never improves on its own and you can't get better smell test scoring by optimistically thinking it's better

I was in a clinical trial and received mesenchymal stromal cells. The final data is not yet published, I saw the prelim data which hadn't yet indicated which arm was placebo, low-dose, or high-dose. The arms all showed improvements though and no one stood out as far worse than the other two, so it didn't appear all that different than placebo.

At the conclusion of the study I was unblinded and told for sure I got the high-dose arm. Did it help, though? Can't say. I've not progressed much but wasn't progressing much before or after the treatment period either. I still have pretty bad periods of symptoms at times. Maybe they would have gotten worse without this treatment, but I can't know that.

It was a great opportunity for me to try them for free with the benefit of high quality control used for a US clinical trial. There is no released proof of their usefulness for PD and I wouldn't recommend spending your money on this.

Dr. Barker discussed the history and current state of cell-based transplantation for Parkinson's disease. He explained that fetal dopamine cells, taken from the developing midbrain of human fetuses at six to eight weeks of age, have shown promise in preclinical models. These cells can survive long-term, connect with the brain, release dopamine, and improve symptoms in animal models. Early clinical trials in the late 1980s demonstrated significant improvement in patients, including one who went from being off medication for two-thirds of the day to being on all day after receiving a transplant. Imaging studies confirmed the restoration of dopamine at the transplantation site. However, Dr. Barker noted that past trials have had mixed results due to issues like trial design, patient selection, and post-surgery immunosuppression. Efforts are ongoing to improve trial methodologies and clarify the efficacy of cell-based therapies.

Dr. Barker discussed the challenges and potential of cell-based transplantation for Parkinson's disease. He noted that while fetal dopamine cells can be highly effective when successful, the results have been inconsistent due to issues like trial design and patient selection. He expressed concerns about current trials, particularly those asking patients to pay, as they lack robust preclinical evidence and could harm the field if they fail or cause harm. Dr. Barker emphasized the importance of careful trial design and warned against poorly conceived trials that could jeopardize progress in cell-based therapies.

This paper reviewed recent progress in using stem cells to develop therapies for Parkinson's disease. It focused on creating dopamine-producing neurons to replace those lost in the brain due to the disease.

The study found that stem cell-based therapies show promise in restoring motor functions by integrating transplanted cells into the brain and forming synapses. However, challenges remain, such as ensuring the cells do not proliferate excessively or form tumors.

For someone with Parkinson's, this research highlights hope for future treatments that could improve motor function and quality of life, though it is not a cure. It emphasizes the importance of ongoing research to address safety and effectiveness concerns.

This paper is reliable as it is published in a reputable journal focused on movement disorders and provides a comprehensive review of recent advancements in the field.

This paper systematically reviewed and analyzed clinical trials on cell-based therapies for Parkinson's disease, focusing on treatments using homogenous cells (one cell type). It evaluated the effects of these therapies on disease severity and motor function over various follow-up periods.

The study found that homogenous cell-therapy improved motor function and daily living activities in Parkinson's patients, particularly in the 'off' state, with benefits lasting up to 36 months. Allogeneic cells (from donors) were more effective than autologous cells (from the patient), and transplantation sites outside the basal ganglia also showed positive results.

For individuals with Parkinson's, this research suggests that cell-based therapies could offer long-term improvements in motor function and daily activities, especially for those who respond to levodopa. It also highlights the potential of donor-derived cells and flexible transplantation sites as effective treatment options.

This paper is a systematic review and meta-analysis, which is a high-quality research method. It was published in the reputable Journal of Translational Medicine, and the findings are based on data from 11 independent trials involving 210 patients, making it a reliable source of evidence.